Christopher Banfield

Christopher Banfield

Auto-generated profile, based on publicly available information

Christopher Banfield

Clinical Pharmacology, Pfizer, Cambridge, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KPKaren M. Page
Karen M. Page
MSMayte Suarez-Farinas
Mayte Suarez-Farinas
MSMaria Suprun
Maria Suprun
WZWeidong Zhang
Weidong Zhang
SGSandra Garcet
Sandra Garcet
EPElena Peeva
Elena Peeva

1 July 1997 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
PGPaul Glue
Paul Glue
WSW. Sulowicz
W. Sulowicz
RCR. Colucci
R. Colucci
CBC. Banfield
C. Banfield
SPS. Pai
S. Pai
MAM. B. Affrime
M. B. Affrime
Aims The purpose of this study was to evaluate the effects of renal impairment on the single‐dose pharmacokinetics of the antiepileptic felbamate. Methods Twelve subjects with three levels of renal dysfunction (creatinine clearance >30–80, >10–30 or 5–10 m min−1 ) and four controls with normal renal function (creatinine clearance >80 ml min−1 were studied). Plasma and urine samples were obtained for 144 h following administration of a single 1200 mg dose. Results Compared with controls, apparent total body clearance, renal clearance and urinary excretion of felbamate were decreased, and half‐life, Cmax and AUC values were increased in subjects with renal dysfunction. The magnitude of these changes was associated with the degree of renal dysfunction. Nonrenal clearance and apparent volume of distribution values were also lower in renal dysfunction subjects, but there was no association between the extent of these changes and degree of renal dysfunction. Renal clearance of felbamate accounted for approximately 30% of apparent total body clearance in the control group and from 9–22% in the renal failure patients. Renal clearance of felbamate was significantly correlated with creatinine clearance (r2=0.75; P<0.001). Conclusions These data suggest that initial dosage and titration of felbamate may require adjustment in patients with renal dysfunction.

1 January 2002 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
SGSamir K. Gupta
Samir K. Gupta
CBChristopher Banfield
Christopher Banfield
MAMelton Affrime
Melton Affrime
AMAliceann Marco
Aliceann Marco
MCMitchell Cayen
Mitchell Cayen
DPDesmond Padhi
Desmond Padhi

1 April 1996 in American Journal of Therapeutics
Verified
Journal Article
Closed access
RCR. Colucci
R. Colucci
PGPaul Glue
Paul Glue
CBC. Banfield
C. Banfield
PRP. Reidenberg
P. Reidenberg
JMJ. Meehan
J. Meehan
MAM. Affrime
M. Affrime
To assess the possible interaction between clonazepam and felbamate, a double-blind, randomized, placebo-controlled, two-way crossover study was conducted in 18 healthy male volunteers. Volunteers were administered clonazepam (1 mg q12h) and felbamate (1200 mg q12h) or matching placebo for 10 days during each period of the crossover. Following morning dosing on day 10, blood samples were obtained over 12 h for the determination of clonazepam and the metabolites 7-amino-clonazepam and 7-acetamido-clonazepam. Felbamate increased clonazepam's Cmax and AUC0–12h by 17% and 14%, respectively (p<0.01). The 90% confidence intervals following log-transformation for each of these pharmacokinetic parameters were within the generally accepted interval (80–125%) for bioequivalence. Felbamate had no significant effect on the pharmacokinetics of 7-amino-clonazepam, whereas 7-acetamido-clonazepam concentrations were below the limit of quantification in all but one subject. Adverse events were mainly central nervous system in nature, with a greater incidence reported during coadministration with felbamate compared with placebo. Overall, felbamate appears to have no clinically relevant effects on the pharmacokinetics of clonazepam.

8 February 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
FMFarzaneh Maleki
Farzaneh Maleki
ECElias Clark
Elias Clark
CBChristopher Banfield
Christopher Banfield
WBWonkyung Byon
Wonkyung Byon
TNTimothy Nicholas
Timothy Nicholas
The objective of this population pharmacokinetic (PK) analysis was to characterize the concentration–time profile of brepocitinib plasma concentration after single‐ and multiple‐oral administration in healthy volunteers (HVs) and patients with immuno‐inflammatory diseases. Blood samples from phase I HV and phase II clinical studies of patients with alopecia areata, psoriasis, psoriatic arthritis, ulcerative colitis (UC), vitiligo, and hidradenitis suppurativa were analyzed using a nonlinear mixed‐effects modeling approach. Effects of patients' characteristics on brepocitinib exposure were investigated. Overall, 8552 brepocitinib plasma concentrations from 775 individuals were included in the analysis. The PKs of brepocitinib were adequately described by a two‐compartment model with first‐order absorption and a lag time for tablet formulation, dose‐dependent bioavailability, and Box–Cox transformed interindividual variabilities on apparent clearance (CL/F) and apparent central volume of distribution (Vc/F). For a typical 70‐kg non‐Asian female patient with baseline aspartate aminotransferase of 22 unit/liter, CL/F and Vc/F estimates were 17.5 L/h and 88.5 L, respectively. Asians had a higher exposure (independent of body weight), caused by a 10% lower CL/F when compared to other individuals. Independent of baseline body weight, the male population showed 13% higher Vc/F compared to the female population. Patients with UC were predicted to have 46% slower absorption rate compared to other individuals. The PKs of brepocitinib were well‐characterized by a two‐compartment model with first‐order absorption and dose‐dependent bioavailability. Several covariates, such as race and sex, were identified to have statistically significant, but not clinically meaningful, effects on the estimated PK parameters.

24 March 2026 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
JPJohn Prybylski
John Prybylski
JZJing Zhu
Jing Zhu
CBChristopher Banfield
Christopher Banfield
AMArnab Mukherjee
Arnab Mukherjee
VPVivek Purohit
Vivek Purohit
Dermatomyositis (DM) is a rare and debilitating inflammatory disease associated with muscle weakness and skin manifestations. As with all rare diseases, clinical trials in DM are challenging due to the small number of patients available for study, and DM patients may even present with skin- or muscle-predominant disease. A Phase 2 study of an anti-interferon-beta monoclonal antibody (dazukibart) in DM was recently completed. Most trial data were collected in skin-predominant DM patients, measuring the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI); the Total Improvement Score (TIS) was only measured in a small subset of muscle-predominant DM patients. Because TIS is a more holistic endpoint, planning for further dazukibart development depended on a robust understanding of TIS response. This analysis aimed to develop an exposure-response model for dazukibart in DM patients. The model was intended to describe the timecourses of all relevant clinical responses, including CDASI and TIS, using the available data to collectively inform the exposure-response relationships. The model provided evidence for a TIS response in DM patients treated with dazukibart that was consistent with the observed data and supportive of further development. The model used here could be applied directly to model-based meta-analysis of other DM trials, and the general approach can be used in rare diseases with multiple endpoints. Trial registration numbers: NCT03181893, NCT02766621.